Biocon stock ticks up as Yesafili Biosimilar clinical data gets published in peer-reviewed journals
1h agoen
From the article
CEO Shreehas Tambe called the publications an important milestone for the company’s aflibercept biosimilar programme
Continue reading on thehindubusinessline.comYou might also wanna read
Recent moves of note in and around the biotech and pharma industries
nature.com·13d ago
Celltrion Poised for Profitability Leap on New Biosimilars
Seoul Economic Daily·3d ago
Taking the Pulse of BioPharma: The Industry Today and Trends of Tomorrow
bioprocessintl.com·11h ago
ASO biotech wants MHRA to go further in new rare disease therapy framework
bioprocessintl.com·26d ago
Biosimilar Success in an Evolving Landscape: Development Considerations for Staying Competitive
bioprocessintl.com·11d ago
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
Bars·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.